Thalidomide: An antineoplastic agent
- Robert J. Amato DO
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
It has been more than three decades since the withdrawal of thalidomide from the marketplace. Thalidomide is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. Current evidence indicates that thalidomide reduces the activity of the inflammatory cytokine tumor necrosis factor-á by accelerating the degradation of its messenger RNA. Thalidomide inhibits angiogenesis. Recently, thalidomide was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen’s disease. Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet’s syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation. Many recent studies have evaluated thalidomide in patients with HIV infection, in which this drug is an efficacious agent against oral aphthous ulcers, HIV-associated wasting syndrome, HIV-related diarrhea, and Kaposi’s sarcoma. Only in the last several years has thalidomide been aggressively investigated for its antiangiogenic potential and immunomodulatory properties in various tumor types. Current research on thalidomide in oncology covers investigation in a wide range of both solid tumors and hematologic malignancies.
- Manson JM: Teratogens. In Casarett and Doull’s Toxicology: The Basic Science of Poisons, edn 3. Edited by Klassen CD, Amdur MO, Doull J. New York: Macmillan; 1986:195–220.
- Muller GW.: Thalidomide: from tragedy to new drug discovery. Chemtach. 1997, 27:21–25.
- Sampaio EP, Sarno EN, Galilly R, et al.: Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med 1991, 173:699–703. CrossRef
- Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965, 6:303–306.
- Tseng S, Pak G, Washenik K, et al.: Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996, 35:969–979. CrossRef
- Somers GE. Pharmacological properties of thalidomide (alpha-phtalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960, 15:111–116.
- Gad SM, Shannon EJ, Krotoski WA, et al.: Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. LEPR Rev 1985; 56:35–39.
- Nogueira AC, Neubert R, Helge H, Neubert D: Thalidomide and the immune system: simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sciences 1994, 66:77–92. CrossRef
- Hellman K, Duke DI, Tucker DF: Prolongation of skin homograft survival by thalidomide. BMJ 1965, 2:687–689.
- Murphy GP, Mirand EA, Groenewald JH, et al.: Erythropoietin release in renal allografted baboons, with and without immunosuppression. Invest Urol 1970, 7:271–282.
- Makonkaweyoon S, Limson-Pobre RNR, Moreira AL, et al.: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1993; 90:5974–5978. CrossRef
- Haslett P, Hempstead M, Seidman C, et al.: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Human Retrovir 1997, 13:1047–1054.
- Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. J Acq Immune Def Syndr Human Retrovir 1996, 11:247–257.
- Moriera AL, Sampaio EP, Zmuidznias A, et al.: Thalidomide exerts its uninhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177:1675–1680. CrossRef
- Sampaio EP, Kaplan G. Miranda A, et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 68:408–414.
- D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082–4085. The effect of thalidomide on growing vessels is observed only when the drug is administered systemically, suggesting the need for formation of an active metabolite in vivo. CrossRef
- Kenyon BM, Browne F, D’Amato R: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Eye Res 1997, 64:971–978. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor. CrossRef
- Somers GE: Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960, 15:111–116.
- Chen T-L, Vogelsang GB, Petty BG, et al.: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing healthy male volunteers. Drug Metab Dispos 1989, 17:402–405.
- Fabro S, Schumacher H, Smith RL, et al.: The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br J Pharmacol 1965, 25:352–362.
- Schumacher H, Smith RL, Williams RT: The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 1965, 25:325–337.
- Schumacher H, Smith RL, Willians T: The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965, 25:338–351.
- Iyer CGS, Languillon J, Ramanujam K, et al.: WHO coordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Org 1971, 45:719–732.
- Hastings RC, Trautman JR, Enna CD, Jacobson RR: Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum. Clin Pharmacol Ther 1970, 11:481–487.
- Pearson JMH, Vedaigiri M: Treatment of moderately severe erythema nodosum leprosum with thalidomide I: a double-blind controlled trial. Lepr Rev 1969, 40:111–116.
- Sheskin J: Further observation with thalidomide in lepra reactions. Lepr Rev 1969, 37:135–146.
- Waters MFR: An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971, 42:26–42.
- Alexander LN, Wilcox CM: A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Human Retrovir 1997, 13:301–304. CrossRef
- Louvel D, Musso S, Metivier S, et al.: Idiopathic esophageal ulceration associated with human immunodeficiency virus infection efficacy of thalidomide treatment. Endoscopy 1996, 28:471–472.
- Bonnetblanc JM, Royer C, Bedane C: Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology 1996, 193:321–323. CrossRef
- Soler RA, Howard M, Brink NS, et al.: Regression of AIDSrelated Kaposi’s sarcoma during therapy with thalidomide. Clin Infect Dis 1996, 23:501–503.
- Politi P, Reboredo G, Losso M, et al.: Phase I trial of thalidomide (T) in AIDS-related Kaposi sarcoma (KS) [abstract]. Proc ASCO 1998, 17:41a.
- Little RF, Wyville KM, Pluda JM, et al.: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000, 18:2593–2602.
- Fine HA, Figg WD, Jaeckle K, et al.: Phase II trial of the antiangiogenic agent, thalidomide, in patients with recurrent high grade gliomas. J Clin Oncol 2000, 18:708–715. The investigators note that thalidomide is well tolerated and may have some biologic activity in this population.
- Glass J, Gruber ML, Nirenberg A: Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme [abstract]. Proc ASCO 1999, 18:551.
- Figg WD, Bergan R, Brawley O, et al.: Randomized phase II study of thalidomide in androgen-indpendent prostate cancer(AIPC)[abstract]. Proc ASCO 1997, 16:333.
- Singhal S, Mehta J, Eddlemon P, et al.: Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) [abstract]. Blood 1998, 92(suppl 1):318a. The authors concluded that thalidomide has remarkable antitumor activity in advanced and high-risk multiple myeloma and should be considered for incorporation into combination trials.
- Baidas SM, Winer EP, Fleming GF, et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000, 18:2710–2717.
- Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571. CrossRef
- Desikan R, Munshi N, Zeldis J, et al.: Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. Presented at the American Society of Hematology 41st Annual Meeting. New Orleans, LA December 3–7, 1999. (abstract 2685).
- Sabir T, Raza S, Anderson L, Jagannath S: Thalidomide is effective in the treatment of recurrent refractory multiple myeloma (MM) [abstract]. Presented at the American Society of Hematology 41st Annual Meeting. December 3–7, 1999. New Orleans, LA (abstract 548).
- Fonseca R, Dispenzieri A, Lacy MQ, et al.: Thalidomide in the treatment of relapsed and refractory myeloma. Presented at the American Society of Hematology 41st Annual Meeting. December 3–7, 1999. New Orleans, LA (abstract 1414).
- Schiller G, Vescio R, Berenson J: Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. Presented at the American Society of Hematology 41st Annual Meeting. December 3–7, 1999. New Orleans, LA (abstract 1417).
- Durie BGM, Stepan DE: Efficacy of low dose thalidomide (T) in multiple myeloma. Presented at the American Society of Hematology 41st Annual Meeting. December 3–7, 1999. New Orleans, LA (abstract 1413).
- Eisen T, Boshoff C, Mak I, et al.: Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812–817. The authors conclude that further studies using thalidomide at higher doses as a single agent for renal cell cancer and in combination with biochemotherapy regimens are warranted. CrossRef
- Minor D, Elias L: Thalidomide treatment of metastatic renal cell carcinoma [abstract]. Proc ASCO 2000, 19:1384.
- Thalidomide: An antineoplastic agent
Current Oncology Reports
Volume 4, Issue 1 , pp 56-62
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, 77030, Houston, TX, USA